Please go to Enter Survey & provide your feedback on Ellen Licking's talk on What Cancer Pathways Mean for the Biopharma Industry.

The Bio2Device Group (B2DG) is a premier organization for all San Francisco Bay Area professionals in pharmaceutical, biotech, medical device, diagnostics and other life science industry sectors. Weekly programs are designed to keep members up-to-date with industry news, help them explore other industry sectors, and provide networking opportunities with other life science professionals from all industry sectors and corporate functions. The B2DG also hosts a moderated LinkedIn Group to facilitate communication between members.

Our Next Event

Ellen Licking - Senior Editor and Analyst - Value & Innovation LLC, a subsidiary of Real Endpoints
05/22/2012 - 8:30am
Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)

Topic Description
Only a few years old, results from existing “cancer pathway” pilots underway at national and regional insurers are being unveiled in 2012. If these experiments in using evidence-based medicine to improve outcomes and lower costs prove successful, drug companies will have to adapt their drug development and commercialization strategies to drive market uptake of their...

Syndicate content